Keywords: AstraZeneca, Caprelsa, Germany, IQWiG, AMNOG, Thyroid cancer

Germany's IQWiG finds no proof of added benefit for AstraZeneca's Caprelsa in thyroid cancer

Article | 05 July 2012

Print This

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of Anglo-Swedish drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in